Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar;34(2):882-889.
doi: 10.1111/jvim.15723. Epub 2020 Feb 16.

Concurrent use of rabacfosadine and L-asparaginase for relapsed or refractory multicentric lymphoma in dogs

Jacob R Cawley  1 , Zachary M Wright  2 , Karri Meleo  3 , Gerald S Post  4 , Craig A Clifford  5 , Kathryn R Vickery  5 , David M Vail  6 , Philip J Bergman  7 , Douglas H Thamm  1   8   9
Affiliations

Concurrent use of rabacfosadine and L-asparaginase for relapsed or refractory multicentric lymphoma in dogs

Jacob R Cawley et al. J Vet Intern Med. 2020 Mar.

Erratum in

Abstract

Background: Rabacfosadine (RAB), a novel antineoplastic agent conditionally licensed for the treatment of lymphoma in dogs, is efficacious in both naïve and previously treated dogs. Its use in combination with L-asparaginase (L-ASP) has not been studied.

Hypothesis/objectives: To evaluate the safety and efficacy of L-ASP given concurrently with RAB in dogs with relapsed multicentric lymphoma.

Animals: Fifty-two dogs with relapse of lymphoma after treatment with at least 1 doxorubicin-based chemotherapy protocol.

Methods: Open-label, multicenter, prospective single-arm clinical trial. Dogs were treated with RAB at 1.0 mg/kg IV every 21 days for up to a total of 5 doses. L-asparaginase was administered at 400 IU/kg SQ concurrently with the first 2 treatments of RAB.

Results: The overall response rate (ORR) for all dogs was 67%, with 19 dogs (41%) achieving a complete response (CR). The median progression-free survival time (MPFS) was 63 days (range 5-428 days). Dogs experiencing a CR as their best response had an MPFS of 144 days (range 44-428 days). Adverse events were similar to previous studies evaluating single agent RAB. Failure to achieve a CR and having previously received L-ASP were negative prognostic factors on multivariate analysis.

Conclusions and clinical importance: Concurrent RAB/L-ASP appears to be both efficacious and safe for treating relapsed multicentric lymphoma in dogs. Adverse events were most often mild and no unexpected toxicoses were observed.

Keywords: GS-9219; Tanovea; asparaginase; chemotherapy; dog; guanine; lymphosarcoma.

PubMed Disclaimer

Conflict of interest statement

Douglas H. Thamm is a consultant for and shareholder in VetDC. Karri Meleo, Gerald S. Post, Kathryn R. Vickery, David M. Vail, and Philip J. Bergman are members of VetDC's Clinical Advisory Board.

Figures

Figure 1
Figure 1
Kaplan‐Meier curve depicting the effects of immunophenotype on progression free interval. P values indicate univariate log‐rank values (n = 42). Tick marks indicate censored patients
Figure 2
Figure 2
Kaplan‐Meier curve depicting the effects of previous L‐ASP treatment on progression‐free interval. P values indicate univariate log‐rank values (n = 42). Tick marks indicate censored dogs
Figure 3
Figure 3
Response rates for dogs treated with RAB/L‐ASP based on (A) number of previous lines of treatment before treatment with RAB/L‐ASP, (B) previous treatment with L‐ASP (n = 46)
Figure 4
Figure 4
Kaplan‐Meier curves depicting the effects of number of previous lines of treatment before RAB/L‐ASP on progression‐free interval. P values indicate univariate log‐rank values (n = 42). Tick marks indicate censored dogs
Figure 5
Figure 5
Response rates based on immunophenotype for dogs treated with RAB/L‐ASP (n = 46)
See this image and copyright information in PMC

References

    1. Zemann BI, Moore AS, William RM, et al. A combination chemotherapy protocol (VELCAP‐L) for dogs with lymphoma. J Vet Intern Med. 1998;12:465‐470. - PubMed
    1. Vail DM, Thamm DH, Reiser H, et al. Assessment of GS‐9219 in a pet dog model of non‐Hodgkin's lymphoma. Clin Cancer Res. 2009;15(10):3503‐3510. - PubMed
    1. Reiser H, Wang J, Chong L, et al. GS‐9219—a novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non‐Hodgkin's lymphoma. Clin Cancer Res. 2008;14(9):2824‐2832. - PubMed
    1. Saba CF, Vickery KR, Clifford CA, et al. Rabacfosadine for relapsed canine B‐cell lymphoma: efficacy and adverse event profiles of 2 different doses. Vet Comp Oncol. 2017;16(1):E76‐E82. - PubMed
    1. Panosyan EH, Grigoryan RS, Avramis IA, et al. Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG‐1961). Anticancer Res. 2004;24(2C):1121‐1125. - PubMed

MeSH terms

Grants and funding